Skip to main content

Gowthami Morey Arepally

Professor of Medicine
Medicine, Hematology
Duke Box 3486, Durham, NC 27710
Rm 356A Sands Bldg, Research Drive, Durham, NC 27710

Overview


Gowthami M. Arepally, M.D. is a Professor of Medicine in the Division of Hematology at Duke University Medical Center.  Her clinical interests are in immune thrombocytopenias, thrombotic disorders, and complement-mediated diseases.  Dr. Arepally’s long-standing research program investigates the immune pathogenesis of heparin induced thrombocytopenia (HIT).  Current laboratory efforts focus on the role of complement activation in antibody production and thrombosis in HIT, studies of complement inhibitors for immune-complex mediated diseases and diagnostic biomarkers of platelet activation.  

Current Appointments & Affiliations


Professor of Medicine · 2018 - Present Medicine, Hematology, Medicine
Associate Professor of Pathology · 2009 - Present Pathology, Clinical Science Departments
Professor of Pathology · 2018 - Present Pathology, Clinical Science Departments

In the News


Published August 2, 2023
Shaping the Future of Medicine by Providing Medical Students With Hands-on Lab Training
Published February 1, 2021
Addressing Diversity in Science, at a Personal and Institutional Level

View All News

Recent Publications


Escherichia coli Type III Secretion System 2 (ETT2) is Associated with Patient Mortality in Bloodstream Infections.

Journal Article J Infect Dis · May 22, 2025 BACKGROUND: Escherichia coli has an extensive accessory genome, though its role in impacting patient mortality is unknown. METHODS: We performed whole genome sequencing with E. coli bloodstream infection isolates from inpatients at Duke University. Pan-gen ... Full text Link to item Cite

Structural and functional changes underlying activation of monocytes in heparin-induced thrombocytopenia.

Journal Article J Thromb Haemost · May 2025 BACKGROUND: Heparin-induced thrombocytopenia (HIT) is an antibody-mediated disorder associated with thrombosis developing in response to anticoagulation with heparin. Monocytes targeted by HIT antibodies contribute to the prothrombotic state, but structura ... Full text Link to item Cite

Complement activation as a biomarker for platelet-activating antibodies in heparin-induced thrombocytopenia.

Journal Article J Thromb Haemost · March 2025 BACKGROUND: Immunoglobulin G antibodies (Abs) to platelet factor 4 (PF4) complexed to heparin (PF4/H) commonly occur after H exposure but cause life-threatening complications of H-induced thrombocytopenia (HIT) in only a few patients. Presently, only plate ... Full text Link to item Cite
View All Publications

Recent Grants


Mid-Atlantic praGmatic NETwork for Inclusive Clinical trials in emergency care (MAGNETIC)

ResearchCollaborator · Awarded by National Institute of Neurological Disorders and Stroke · 2023 - 2028

Stimulating Access to Research in Residency (StARR) - NHLBI

Inst. Training Prgm or CMEPreceptor · Awarded by National Heart, Lung, and Blood Institute · 2018 - 2028

View All Grants

Education, Training & Certifications


Vanderbilt University · 1989 M.D.

External Links


Arepally Lab